78 related articles for article (PubMed ID: 21332051)
1. Phospholamban gene mutations are not associated with hypertrophic cardiomyopathy in patients from southern Poland.
Petkow-Dimitrow P; Kieć-Wilk B; Kwaśniak M; Mikołajczyk M; Dembińska-Kieć A
Kardiol Pol; 2011; 69(2):134-7. PubMed ID: 21332051
[TBL] [Abstract][Full Text] [Related]
2. Phospholamban gene mutations are not associated with hypertrophic cardiomyopathy in a Northern Greek population.
Kalemi T; Efthimiadis G; Zioutas D; Lambropoulos A; Mitakidou A; Giannakoulas G; Vassilikos V; Karvounis H; Kotsis A; Parharidis G; Louridas G
Biochem Genet; 2005 Dec; 43(11-12):637-42. PubMed ID: 16382369
[TBL] [Abstract][Full Text] [Related]
3. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing.
Landstrom AP; Adekola BA; Bos JM; Ommen SR; Ackerman MJ
Am Heart J; 2011 Jan; 161(1):165-71. PubMed ID: 21167350
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives.
Andersen PS; Havndrup O; Hougs L; Sørensen KM; Jensen M; Larsen LA; Hedley P; Thomsen AR; Moolman-Smook J; Christiansen M; Bundgaard H
Hum Mutat; 2009 Mar; 30(3):363-70. PubMed ID: 19035361
[TBL] [Abstract][Full Text] [Related]
5. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ
Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405
[TBL] [Abstract][Full Text] [Related]
6. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
[TBL] [Abstract][Full Text] [Related]
7. Selected mutations in the myosin binding protein C gene in the Polish population of patients with hypertrophic cardiomyopathy.
Rudziński T; Selmaj K; Drozdz J; Krzemińska-Pakuła M
Kardiol Pol; 2008 Aug; 66(8):821-5; discussion 826-7. PubMed ID: 18803133
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy.
Van Driest SL; Jaeger MA; Ommen SR; Will ML; Gersh BJ; Tajik AJ; Ackerman MJ
J Am Coll Cardiol; 2004 Aug; 44(3):602-10. PubMed ID: 15358028
[TBL] [Abstract][Full Text] [Related]
9. Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C>G mutation.
Medin M; Hermida-Prieto M; Monserrat L; Laredo R; Rodriguez-Rey JC; Fernandez X; Castro-Beiras A
Eur J Heart Fail; 2007 Jan; 9(1):37-43. PubMed ID: 16829191
[TBL] [Abstract][Full Text] [Related]
10. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy.
Olson TM; Doan TP; Kishimoto NY; Whitby FG; Ackerman MJ; Fananapazir L
J Mol Cell Cardiol; 2000 Sep; 32(9):1687-94. PubMed ID: 10966831
[TBL] [Abstract][Full Text] [Related]
11. Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy.
Minamisawa S; Sato Y; Tatsuguchi Y; Fujino T; Imamura S; Uetsuka Y; Nakazawa M; Matsuoka R
Biochem Biophys Res Commun; 2003 Apr; 304(1):1-4. PubMed ID: 12705874
[TBL] [Abstract][Full Text] [Related]
12. Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences.
Doolan A; Tebo M; Ingles J; Nguyen L; Tsoutsman T; Lam L; Chiu C; Chung J; Weintraub RG; Semsarian C
J Mol Cell Cardiol; 2005 Feb; 38(2):387-93. PubMed ID: 15698845
[TBL] [Abstract][Full Text] [Related]
13. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy.
DeWitt MM; MacLeod HM; Soliven B; McNally EM
J Am Coll Cardiol; 2006 Oct; 48(7):1396-8. PubMed ID: 17010801
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype.
Kubo T; Gimeno JR; Bahl A; Steffensen U; Steffensen M; Osman E; Thaman R; Mogensen J; Elliott PM; Doi Y; McKenna WJ
J Am Coll Cardiol; 2007 Jun; 49(25):2419-26. PubMed ID: 17599605
[TBL] [Abstract][Full Text] [Related]
15. A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations.
Truszkowska GT; Bilińska ZT; Kosińska J; Śleszycka J; Rydzanicz M; Sobieszczańska-Małek M; Franaszczyk M; Bilińska M; Stawiński P; Michalak E; Małek ŁA; Chmielewski P; Foss-Nieradko B; Machnicki MM; Stokłosa T; Ponińska J; Szumowski Ł; Grzybowski J; Piwoński J; Drygas W; Zieliński T; Płoski R
BMC Med Genet; 2015 Apr; 16():21. PubMed ID: 25928149
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies.
Fish M; Shaboodien G; Kraus S; Sliwa K; Seidman CE; Burke MA; Crotti L; Schwartz PJ; Mayosi BM
Sci Rep; 2016 Feb; 6():22235. PubMed ID: 26917049
[TBL] [Abstract][Full Text] [Related]
17. Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic cardiomyopathy.
Arimura T; Bos JM; Sato A; Kubo T; Okamoto H; Nishi H; Harada H; Koga Y; Moulik M; Doi YL; Towbin JA; Ackerman MJ; Kimura A
J Am Coll Cardiol; 2009 Jul; 54(4):334-42. PubMed ID: 19608031
[TBL] [Abstract][Full Text] [Related]
18. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling.
Ingles J; Doolan A; Chiu C; Seidman J; Seidman C; Semsarian C
J Med Genet; 2005 Oct; 42(10):e59. PubMed ID: 16199542
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel MYBPC3 gene variant in a patient with hypertrophic cardiomyopathy.
Brion M; Allegue C; Gil R; Blanco-Verea A; Carracedo A; Pagannone E; Evangelista A; Di Castro S; Marchitti S; Stanzione R; Volpe M; Rubattu S
Ann Clin Lab Sci; 2010; 40(3):285-9. PubMed ID: 20689143
[TBL] [Abstract][Full Text] [Related]
20. A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy.
Vasile VC; Ommen SR; Edwards WD; Ackerman MJ
Biochem Biophys Res Commun; 2006 Jul; 345(3):998-1003. PubMed ID: 16712796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
